TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: serum low-density lipoprotein-cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: bacteriological success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory lung function parameters (FEV1, FEF50, FEF25, FEF25/75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bronchospasm development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement on the SI-R
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: National Institutes of Health Chronic Prostatitis Symptom Index total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Choroidal blood flow (OBFa, OBFv, POBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Inflammation in the eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % predicted FVC improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in total score of O'Leary‐Sant Interstitial Cystitis Symptoms/Problems Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in Health Related Quality of Life domains
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Alleviation of negative symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Roxithromycin concentration in gastric juice
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Roxithromycin concentration in gastric tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Likelihood of making a quit attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic recurrence of uncomplicated cystitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maternal serum CRH concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Placental CRH expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in maternal serum ALT, AST and TBA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First morphine demand time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stent-associated thrombosis (SAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative healing rate at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients free from heartburn after 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients free of all reflux related symptoms after 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS score in the worst pain during last week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tocilizumab exposure (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tocilizumab exposure (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tocilizumab exposure (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject's Global Assessment of Relief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: sitting functional points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: latissimus dorsi RMS signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: total effective rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients with urinary tract infection
Endpoint domain: Adverse events/effects
Primary endpoint: Positive CLO test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Active ulcer healing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in clinical status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occlusion of patent tubules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance to exercises
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased fall risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: breast self-examination behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: average actual wear rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of pancreatic fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Hospital readmission rate for complications
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: oxidized LDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: serum SOD activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: leukocyte mtDNA deletion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: averaged percent error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fU-OHpr/creat ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone turnover outcomes
Primary endpoint: Reduction in IGF‐I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Elevations of GH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Increased GHBP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Transverse dental expansion in the first molar
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in CFT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in Hb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving Hb increase ≥1 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive attitudes and behaviors towards tobacco-use cessation counseling
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Assessment of patients' willingness to quit and assistance with quitting process
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Advice and assistance received by patients using tobacco
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infectious complication rates
Endpoint domain: Adverse events/effects
Primary endpoint: Wheal response to bradykinin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plaque index reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Health-Related Quality of Life (HRQL) measured by EQ-VAS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Health-Related Quality of Life (HRQL) measured by SF-36 PCS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Area of the proximal stomach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area of the distal stomach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Nausea symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frequency of life events
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Reduction in circulating RNA load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean CD4+ lymphocyte rise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hair preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of ectopic eruption paths
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: nonectopic eruption percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Bridging bone formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of subsequent aVCFs
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical outcomes as measured by ODI
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Control of reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Calf muscle pump function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Renal complications
Endpoint domain: Adverse events/effects
Primary endpoint: Aesthetic result (mean pink aesthetic score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Soft tissue remodeling (thickness and highness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 10-years breast recurrence-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Time to discontinuation of treatment due to lack of efficacy
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients discontinuing treatment due to intolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of chills
Endpoint domain: Adverse events/effects
Primary endpoint: Median prehospital delay time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low contrast distance visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Superior palpebral conjunctival injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time taken to achieve full enteral feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of androgen combined with CsA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PBMNCs inhibiting normal CFU‐GM growth test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioural Outcomes of Anxiety questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Urinary MA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Biochemical failure-free survival
Endpoint domain: Mortality/survival
Primary endpoint: complete sensory and motor blocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of moderate to severe adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Compliance with bacillus Calmette‐Guerin treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Decrease of PI wound area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unplanned rehospitalisations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Dentin retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lost restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite shrinkage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained POAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VTE or major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: satisfaction score from patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: sedation-related cardiopulmonary complications
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of fever of any intensity
Endpoint domain: Adverse events/effects
Primary endpoint: morbidity and mortality of prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: stool consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lamina propria infiltrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance of acetaminophen and aspirin
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of lung cancer
Endpoint domain: Mortality/survival
Primary endpoint: major recurrence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abdominal perception score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: girth changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum triacylglycerol reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum LDL reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SOD activity increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: risk of substantial graft disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: decrease in minimum lumen diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: final height gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemostatic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of ATP in terminating VTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of immediate termination after ATP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness of ATP in SP patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: lean mass increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apnoea-hypopnoea index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: periprosthetic bone density loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: serum metal ion concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of intraoperative memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: propofol requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: annual cost per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Success rate of venipuncture or intravenous cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: chance to achieve remission after the first course of chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relapse free survival (RFS)
Endpoint domain: Mortality/survival
Primary endpoint: Serum uric acid (SUA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary uric acid (uUA) excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Renal clearance test for uric acid (Cl(UA))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Erectile Dysfunction (ED) after EBRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: help to quit
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: use under stress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Discharge time from hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of FC home-monitoring test-kits used per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean uterine volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of dominant myomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean volume of myomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morpheme usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores during physiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total hydromorphone consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delirium (disorientation to time and/or place)
Endpoint domain: Adverse events/effects
Primary endpoint: recurrence of spontaneous sinus rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: postoperative enzyme levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: final residual diameter stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean quality grade of TR envelopes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of uninterpretable envelopes (grade 0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean luminosity score during 2-dimensional harmonic imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in fruit consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in sedentary behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attempts at insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: TAG level decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total ocular score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk for CHD mortality
Endpoint domain: Mortality/survival
Primary endpoint: liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total volume of propofol used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discharge scores using MMSE and CDT
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Discharge scores using TDT
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: PASI 50 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sPGA score improvement ≥2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adenoma detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: detection rate of advanced adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventricular arrhythmia control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of heterotopic ossification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical outcome at twenty-four months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight at 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: control of hot flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of Ascaris lumbricoides egg count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Increase in hemoglobin counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of children with Tinea capitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Quality of referrals made by nurses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response time to messages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: User rating of information transfer device
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of fully healed ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biofilm Level Index (BLI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque Height Index (PHP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of pro- and anti-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in sensory signs, symptoms, and phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atrial Premature Beats
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ventricular Premature Beats
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Trans fatty acid intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum HDL cholesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes